The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
We expect the global non-invasive prenatal testing market to exhibit a CAGR of 10.70% during 2021-2026.
The high prevalence of genetic disorders in the fetus, along with the rising health awareness towards early disease detection at a primitive stage, is one of the key factors driving the global non-invasive prenatal testing market.
The sudden outbreak of the COVID-19 pandemic had hampered the market growth due to the high risk of coronavirus contraction upon hospital visits for numerous medical procedures involved in the prenatal testing.
Based on the test type, the global non-invasive prenatal testing market can be bifurcated into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, fetal cells in maternal blood tests, and others. Among these, ultrasound detection currently exhibits a clear dominance in the market share.
Based on the application, the global non-invasive prenatal testing market has been divided into trisomy, microdeletions syndrome, and others. Currently, trisomy holds the largest segment.
Based on the end-user, the global non-invasive prenatal testing market can be segmented into hospitals, diagnostic laboratories, and others. Among these, diagnostic laboratories account for the highest market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Currently, North America dominates the global market.
Some of the major players in the global non-invasive prenatal testing market include Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at